Physician profile
Brett W Rhode
NPI 1639147879
$921.73
in general payments reported to CMS, 2019-2025
15 companies · $201 in 2025
The $201 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126 · 2020: $17.44 · 2022: $66.15 · 2023: $159 · 2024: $352 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $712.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $712.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $226.34 | 2023-2025 | |
| Alcon Vision LLC | $153.31 | 2023-2025 | Hydrus Microstent |
| Allergan, INC. | $84.29 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $78.11 | 2019-2022 | |
| Thea Pharma INC. | $71.81 | 2023-2025 | Iyuzeh |
| Rayner Intraocular Lenses Limited | $60.80 | 2022-2024 | Rayone Aspheric, Rayone Spheric, Omidria |
| Astellas Pharma US INC | $52.29 | 2023-2024 | Izervay |
| New World Medical,INC. | $50.86 | 2024 | Streamline, Kahook Dual Blade, Clearpath |
| Regeneron Healthcare Solutions, INC. | $34.83 | 2023 | Eylea |
| Rxsight INC | $21.99 | 2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
| Apellis Pharmaceuticals, INC. | $20.81 | 2025 | Syfovre |
| Amgen INC. | $19.36 | 2025 | Tepezza |
| Harrow Eye, LLC | $18.87 | 2024 | Vevye |
| Horizon Therapeutics Plc | $17.07 | 2023 | Tepezza |
| Omeros Corporation | $10.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Rhode listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.